NCT02695901

Brief Summary

Although several studies have assessed the efficacy of chlorhexidine in treating gingivitis and reducing biofilm formation, the side effects of a long-term use are unpleasant for patients. Melaleuca alternifolia oil has been considered as an alternative because of its anti-inflammatory properties. However, little is know about the efficacy of its nanoparticles. The purpose of this study is to compare the effect of 0.12% chlorhexidine (Periogard ®) and a nanoparticle solution of 0.3% M. alternifolia oil in reducing biofilm formation in plaque-free and plaque-covered teeth surfaces.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
59

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Mar 2016

Shorter than P25 for phase_4

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 21, 2016

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 1, 2016

Completed
Same day until next milestone

Study Start

First participant enrolled

March 1, 2016

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

March 1, 2016

Status Verified

February 1, 2016

Enrollment Period

9 months

First QC Date

February 21, 2016

Last Update Submit

February 29, 2016

Conditions

Keywords

Plaque indexMelaleuca alternifolia oil.Nanoparticles

Outcome Measures

Primary Outcomes (1)

  • Dental plaque/biofilm formation.

    7 days.

Secondary Outcomes (1)

  • Gingival abrasion.

    7 days.

Other Outcomes (2)

  • Gingival crevicular fluid- measured through an electronic gingival fluid measuring device (Periotron®)

    7 days.

  • Perception of appreciation- questionnaire

    7 days.

Study Arms (2)

Chlorhexidine gluconate (0,12%)

EXPERIMENTAL

Subjects will rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%).

Drug: Chlorhexidine gluconate 0.12% (PerioGard®)

M. alternifolia oil (Nanoparticle solution)

EXPERIMENTAL

Subjects will rinse twice daily with 15 ml mouthrinse containing nanoparticles of M. alternifolia oil (0.3%).

Drug: Nanoparticle solution of M. alternifolia oil (0.3%).

Interventions

At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%). Plaque indices will be recorded at baseline, day 4, and day 7.

Chlorhexidine gluconate (0,12%)

At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing a nanoparticle solution of M. alternifolia oil (0.3%). Plaque indices will be recorded at baseline, day 4, and day 7.

M. alternifolia oil (Nanoparticle solution)

Eligibility Criteria

Age18 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Individuals must be systemically healthy;
  • Must have at least six teeth per quadrant;
  • Must not be undergoing medical treatment;

You may not qualify if:

  • Allergies or hypersensitivity to the components (Chlorhexidine Gluconate or M. alternifolia oil nanoparticles);
  • Antibiotic therapy within 3 months prior to baseline examination;
  • History of periodontal disease;
  • Marginal bleeding index higher than 15%;
  • Oral mucosal lesions;
  • Pregnancy or breastfeeding;
  • Presence of active infectious foci (endodontic abscesses);
  • Presence of plaque retentive factors (caries, aesthetic or ill-fitting restorations, orthodontic appliances, fixed or removable prosthesis);
  • Smokers;
  • Systemic conditions (diabetes, immunosuppression);
  • Use of any mouthwash within 21 days prior to baseline examination;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Rahman B, Alkawas S, Al Zubaidi EA, Adel OI, Hawas N. Comparative antiplaque and antigingivitis effectiveness of tea tree oil mouthwash and a cetylpyridinium chloride mouthwash: A randomized controlled crossover study. Contemp Clin Dent. 2014 Oct;5(4):466-70. doi: 10.4103/0976-237X.142813.

    PMID: 25395761BACKGROUND

MeSH Terms

Conditions

Dental Plaque

Interventions

chlorhexidine gluconateChlorhexidine

Condition Hierarchy (Ancestors)

Dental DepositsTooth DiseasesStomatognathic Diseases

Intervention Hierarchy (Ancestors)

BiguanidesGuanidinesAmidinesOrganic Chemicals

Study Officials

  • Fabricio B. Zanatta, PhD

    Adjunct Professor

    STUDY DIRECTOR

Central Study Contacts

Fabricio B. Zanatta, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MsC, Federal University of Santa Maria

Study Record Dates

First Submitted

February 21, 2016

First Posted

March 1, 2016

Study Start

March 1, 2016

Primary Completion

December 1, 2016

Study Completion

December 1, 2016

Last Updated

March 1, 2016

Record last verified: 2016-02